American startup Synchron has launched clinical trials of the Stentrode brain-computer interface, designed to help paralyzed patients. Writes about it Bloomberg.
We’re proud to announce that we’ve achieved a significant milestone for our company and millions of people living with #paralysis. We’ve officially enrolled the first patient in our early feasibility study here in the US. To learn more https://t.co/vHRYtUx9z3 pic.twitter.com/XWtwh6kS4n
— Synchron (@synchroninc) May 4, 2022
The experiment will involve six patients from New York and Pittsburgh, Pennsylvania. One of them has already arrived at the hospital, but Synchron founder and CEO Tom Oxley declined to name him or provide demographic data.
At the first stage, Stentrode must confirm its safety, as well as provide the ability to control digital devices without the help of hands.
Prior to this, Synchron received approvals for short-term laboratory studies. The company believes that if the test is successful, the device can be approved for widespread use on a long-term basis.
Recall that in January Neuralink Elon Musk opened a vacancy for the director of clinical trials.
That same month, scientists developed an AI-powered eye implant that restored sight to a nearly blind woman.
In August 2021, Synchron received approval from the US Food and Drug Administration to conduct human testing of neural interfaces.
Subscribe to Cryplogger news in Telegram: Cryplogger AI – all the news from the world of AI!
Found a mistake in the text? Select it and press CTRL+ENTER
